Green Chemistry Transforming Pharmaceutical Manufacturing in the APAC Region

The Asia-Pacific pharmaceutical industry is adopting green chemistry to boost sustainability, leveraging biocatalysis, renewable feedstocks, and continuous manufacturing to produce drugs more efficiently.

Life Sciences Review | Tuesday, February 17, 2026

In the Asia-Pacific region, growing environmental awareness and the drive for efficiency and sustainability are prompting the pharmaceutical industry to fundamentally rethink drug production. Central to this transformation is green chemistry, a discipline focused on designing chemical products and processes that reduce the use and generation of hazardous substances. This shift is not only an ethical responsibility but also a strategic necessity, fostering a more resilient, cost-effective, and environmentally friendly pharmaceutical ecosystem. Applying these principles to metabolic drug synthesis—a cornerstone of modern medicine—is driving significant advancements and ushering in a new era of sustainable therapeutic development.

The traditional petrochemical-based “brown” model of pharmaceutical manufacturing is increasingly being replaced by greener approaches guided by the twelve principles of green chemistry. These principles, which include waste prevention, atom economy, and the use of safer solvents and catalysts, are being ingeniously applied to address the intricate challenges of synthesizing complex metabolic drugs. The focus is on designing synthetic routes that are not only more efficient in terms of yield but also inherently safer for both the environment and the workforce. This holistic approach, which considers the entire lifecycle of a drug, is fostering a culture of sustainability that permeates every facet of the pharmaceutical value chain.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

The Rise of Biocatalysis: Nature's Green Chemists

A pivotal element in the greening of metabolic drug synthesis is the increasing adoption of biocatalysis. Enzymes are being harnessed to perform intricate chemical transformations with a level of precision and selectivity that is often unattainable with conventional chemical methods. These biological catalysts operate under mild conditions of temperature and pressure, typically in aqueous environments, thereby obviating the need for harsh and energy-intensive reaction conditions. The exquisite stereospecificity of enzymes is particularly advantageous in the synthesis of chiral drugs, which constitute a significant portion of metabolic therapies. By eliminating the need for complex and often wasteful chiral resolution steps, biocatalysis significantly enhances the efficiency and sustainability of the manufacturing process.

The power of biocatalysis is being further amplified through the tools of modern biotechnology. Protein engineering and directed evolution are being employed to tailor enzymes for specific industrial applications, enhancing their stability, activity, and substrate scope. This ability to "design" biocatalysts on demand is opening up new avenues for the synthesis of novel and complex drug molecules that were previously considered synthetically challenging. Furthermore, the integration of multiple enzymatic steps into "one-pot" cascade reactions is streamlining synthetic pathways, reducing the number of intermediate isolation and purification steps, and thereby minimizing waste generation and solvent consumption. This elegant biomimetic approach is not only environmentally friendly but also economically advantageous, leading to shorter production cycles and higher overall yields.

Rethinking Solvents and Feedstocks

The choice of solvents and starting materials is another critical area where green chemistry is making significant inroads. Solvents, which often account for the bulk of the mass in a chemical process, are a major contributor to the environmental footprint of pharmaceutical manufacturing. The industry is actively seeking to replace traditional volatile organic compounds (VOCs) with greener alternatives. Water, the universal solvent, is being increasingly utilized where feasible, along with supercritical fluids like carbon dioxide, which offer the dual benefits of being non-toxic and easily recyclable. Bio-based solvents, derived from renewable resources such as agricultural waste, are also gaining traction as viable and sustainable alternatives.

The shift towards renewable feedstocks is another cornerstone of this green transformation. The exploration of bio-based starting materials is challenging the reliance on finite and environmentally taxing petrochemical resources. Biomass, a rich source of complex and functionalized molecules, is being investigated as a renewable feedstock for the synthesis of key pharmaceutical intermediates. This transition not only reduces the industry's carbon footprint but also aligns with the principles of a circular economy, where waste from one process becomes a valuable resource for another. The development of innovative chemical and biotechnological pathways to convert biomass into high-value pharmaceutical precursors is a vibrant area of research and development in the APAC region.

The Imperative of Process Intensification and Continuous Manufacturing

Beyond the molecular level, green chemistry principles are also being applied to optimize the overall manufacturing process. The concept of process intensification, which aims to develop smaller, safer, and more energy-efficient production technologies, is gaining momentum. A key enabler of this is the transition from traditional batch manufacturing to continuous manufacturing. In a constant process, raw materials are fed into the system, and the final product is collected in an uninterrupted flow. This approach offers numerous advantages over batch processing, including improved product quality and consistency, reduced waste generation, and a smaller manufacturing footprint.

Continuous manufacturing allows for real-time monitoring and control of critical process parameters, ensuring that the reaction conditions are continually optimized. This level of control minimizes the formation of byproducts and impurities, leading to higher yields and purer products. The smaller reaction volumes and enclosed systems inherent in continuous manufacturing also enhance process safety by minimizing the risk of exposure to hazardous materials. The adoption of continuous manufacturing is not only a technological advancement but also a strategic move towards a more agile and responsive pharmaceutical production model, one that is better equipped to meet the evolving demands of the global healthcare landscape.

The integration of green chemistry principles into the fabric of metabolic drug synthesis is catalyzing a profound and positive transformation within the APAC pharmaceutical industry. By embracing the elegance and efficiency of nature's catalysts, reimagining the role of solvents and feedstocks, and optimizing manufacturing processes, the industry is paving the way for a future where the production of life-saving medicines is in harmony with environmental stewardship principles. This green revolution is not merely a fleeting trend but a fundamental shift in mindset, one that recognizes that the long-term health of the planet and its people is inextricably linked. The journey towards a truly sustainable pharmaceutical industry is well underway, with the APAC region firmly positioned at the helm of this critical global endeavor.

More in News

Growing Concerns About Data Continuity in Biopharma Evidence Generation

One of the common concerns within biopharma is not a matter of generating evidence per se. What makes it even harder is the possibility of sustaining a consistent stream of information through several studies or regulations over prolonged periods of time. As such, the issue of data continuity gains more importance as evidence generation software solutions are currently evaluated by potential buyers. Evidentiary initiatives are never limited to the sole scope of their objectives. Information retrieved once can become relevant several times over the life cycle of a particular product. Researchers may need to re-examine certain findings, compare results of treatment between different periods of time or study data acquired within separate research processes. It becomes especially complicated if there are no consistent information sources within an organization. Such considerations begin to impact the choice of evidence generation software. While the tools themselves are hardly ever used to produce any scientific insights directly, their contribution lies in facilitating further evidence processing and management. The problem becomes apparent as evidentiary research programs move past their initial objectives. It is rare for evidence generation initiatives to have a definite deadline or goal. Several years may pass between the start of the research process and its end, which means that there can be many staff changes, reconsiderations of previous assumptions or emergence of new questions. When information proves hard to find or analyze, the whole process can be slowed down significantly. The amount of effort spent tracking documents, verifying the integrity of information and understanding research history may prove to be considerable. At the same time, these aspects might not become a major focus of technology evaluation. Procurement conversations about evidence generation software solutions are shifting in this direction. Buyers' attention moves from operational effectiveness to information sustainability as evidence programs grow more extensive and complex. They are starting to see evidence generation software platforms as tools for sustaining knowledge over time rather than project management resources. This brings a change to the list of priorities for software developers. Features aimed at optimizing research processes are essential but buyers become concerned with data preservation as well. As such, information continuity becomes part of a solution's institutional memory function rather than just another aspect of project management. While data continuity may not be as prominent as some new trends in evidence analytics, it addresses a pressing problem faced by many biopharma teams. Evidence generation projects tend to outlast their budgets, original objectives or even the members of a team conducting research. For biopharma companies investing in such tools, the problem is shifting from acquiring new information to keeping existing data context-sensitive. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Inventus welcomes senior figure from Google as a board adviser

Autologous and Allogeneic Models Push Cell Therapy Toward Different Development Paths

Cell therapy product development is becoming more segmented as autologous and allogeneic products place different demands on design, manufacturing and commercialization. Developers can no longer discuss the sector as one uniform category. Product strategy depends heavily on whether cells come from the patient or from a donor source. Autologous therapies are often built around individualized production. A patient’s own cells are collected, processed and returned as a therapy. This model can create a strong biological fit, but it also places pressure on scheduling, chain of identity, release timelines and site coordination. Every patient-specific batch becomes both a treatment and a manufacturing event. Allogeneic therapies take a different approach. Instead of using each patient's own cells, they rely on donor-derived or engineered cells that can be produced in larger batches and supplied to more patients. This model has the potential to improve access and make therapies more widely available, provided quality, immune compatibility and long-term performance are carefully managed. At the same time, it brings its own set of challenges, including how cells are sourced, how consistently they can be expanded during manufacturing, how they are stored and how different patients may respond to the treatment. Industry analysis from Thermo Fisher Scientific’s Patheon unit notes that autologous therapies require individualized handling because each treatment is tailored to a patient’s cells, while allogeneic therapies must ensure consistent quality and address immune compatibility across recipients. These differences influence product development from the very beginning. For autologous therapies, developers often concentrate on coordinating the entire vein-to-vein process, including logistics, site readiness, rapid release testing and making sure each patient's cells move through the system efficiently. Developers of allogeneic therapies face a different set of priorities, with greater attention on master cell banks, consistency between production batches, inventory management and large-scale quality control. Each approach comes with its own operational challenges, costs and risks that need to be managed throughout development. Manufacturing partners are therefore becoming more specialized. A partner supporting allogeneic production may need scale-up expertise and robust batch release processes. Developers must choose partners based on model fit, not general cell therapy experience alone. Digital systems are becoming important in both pathways. Developers need data continuity from cell collection through manufacturing and administration. Gaps in records can create delays and weaken confidence. Better data handling can support quality review and long-term learning across batches or patient cases. The future of cell therapy product development will likely involve both models advancing in parallel. Autologous and allogeneic approaches solve different problems and face different barriers. The companies best positioned will be those that align biology, manufacturing design, clinical planning and commercial delivery around the specific therapy model they are building. ...Read more

Specials

Green Chemistry Transforming Pharmaceutical Manufacturing in the APAC Region

The Asia-Pacific pharmaceutical industry is adopting green chemistry to boost sustainability, leveraging biocatalysis, renewable feedstocks, and continuous manufacturing to produce drugs more efficiently.